The traditional concept is that CXCL10/CXCL9 largely produced at the tumor site is associated with directing the migration of CXCR3+ effector CD4+ and mostly effector -cytotoxic CD8+ T cells, and CXCR3+ NK cells to the tumor site [167,174,197,198,199,200,201,202]. Here, CD8A is linked to neoplasm.